Strenghten your immuno-oncology research with our complete digital pathology capacities

Drawing on our expertise in multiplexed-immunohistofluoresence (IHF) and immunohistochemistry (IHC) assays, we have already developed and validated a series of markers & panels to assess several markers of interest as well as the abundance and spatial distribution of lymphoid and myeloid immune cell subsets. While bringing key answers to address specific questions, our capacities have recently been highlighted in new scientific publications of collaborative works with Institut Bergonié, which we are delighted to share thereafter.

In the era of immuno-oncology (IO) research, there is a tremendous need to i) gain insights into the mechanisms associated with response to immunotherapies, i.e. sensitivity vs resistance, and to ii) identify novel biomarkers that can help select patients likely to benefit from such immunotherapies, either as single agents or in combination with novel drug candidates. Analysis of tumor samples using reliable technologies such as multiplexed immunohistofluorescence (IHF) & immunohistochemistry (IHC) combined to ground-breaking image analysis capacities offers a valuable approach to meet these current challenges.

Drawing on our expertise in IHC and IHF assays, we have already developed and validated a series of markers & panels to assess several markers of interest as well as the abundance and spatial distribution of lymphoid and myeloid immune cell subsets. In addition to implementing validated panels, Explicyte provides tailor-made services to specifically meet the project needs. Furthermore, in order to get an accurate and comprehensive picture from the tumor sample – i.e. considering tumor cells and their microenvironment – all images obtained through slide digitization are processed for analysis using a very well-trained workflow.

While bringing key answers to address specific questions, our capacities have recently been highlighted in new scientific publications of collaborative works with the Institut Bergonié, which we are delighted to share thereafter.

 

Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial Cousin et al., European Journal of Cancer, 2022

 

In this Phase 2 clinical trial, Cousin et al. demonstrated the benefit of the combination between Regorafenib, a multi Tyrosine Kinase inhibitor, and Avelumab, an anti-PDL1 antibody, in cholangiocarcinoma patients. Analysis of baseline tumor samples through multiplexed-IHF combining CD8 (Green) / CD163 (Yellow) / PD1 (Red) / PDL1 (Orange) / IDO1 (Cyan) / CK19 (White) / DAPI (Blue) markers revealed that responder patients were characterized by a higher expression of PDL1 as well as IDO1.

 

Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study Toulmonde et al., Clinical Cancer Research, 2021

 

In this clinical study evaluating the activity of the combination of Trabectidin and Durvalumab, Toulmonde et al. evidenced encouraging clinical benefit in platinium-refractory ovarian cancer patients. Also, multiplexed-IHC combining PDL1 (Brown), CD8 (Green) as well as CD163 (Purple) highlighted association between PDL1 expression and CD8 infiltration level with Progression Free Survival.